Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Drug
Linker
Peptide
Permeability
Stability
Targeted therapy
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
09
05
2022
revised:
16
06
2022
accepted:
11
07
2022
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
ppublish
Résumé
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development.
Identifiants
pubmed: 36873165
doi: 10.1016/j.apsb.2022.07.020
pii: S2211-3835(22)00332-X
pmc: PMC9978859
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
498-516Informations de copyright
© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Références
J Mol Recognit. 2015 Mar;28(3):173-9
pubmed: 25652594
Mol Cancer Ther. 2019 Nov;18(11):1926-1936
pubmed: 31649014
J Nucl Med. 2018 Nov;59(11):1692-1698
pubmed: 29523629
Curr Med Chem. 2017;24(31):3373-3396
pubmed: 28393694
ChemMedChem. 2015 May;10(5):804-14
pubmed: 25914147
Future Oncol. 2020 Apr;16(11):631-641
pubmed: 32141766
Biopolymers. 2015 Nov;104(6):743-52
pubmed: 26058565
Nat Chem Biol. 2009 Jul;5(7):502-7
pubmed: 19483697
Br J Pharmacol. 2008 Sep;155(2):185-97
pubmed: 18574456
Diabetes Metab Syndr. 2022 Jun;16(6):102511
pubmed: 35623229
Viruses. 2021 Feb 20;13(2):
pubmed: 33672697
Beilstein J Org Chem. 2019 Jan 10;15:96-105
pubmed: 30680044
Expert Opin Investig Drugs. 2020 Oct;29(10):1069-1078
pubmed: 32924646
Int J Nanomedicine. 2012;7:1613-21
pubmed: 22619516
Clin Cancer Res. 2020 Jun 15;26(12):2789-2799
pubmed: 31969331
Int Rev Neurobiol. 2016;130:1-40
pubmed: 27678173
ACS Biomater Sci Eng. 2018 May 14;4(5):1641-1650
pubmed: 33445320
Trends Pharmacol Sci. 2021 Oct;42(10):857-869
pubmed: 34334251
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1621-9
pubmed: 26922351
J Control Release. 2019 Apr 28;300:174-184
pubmed: 30853529
Methods Mol Biol. 2021;2207:327-338
pubmed: 33113145
Bioorg Med Chem. 2018 Jun 1;26(10):2766-2773
pubmed: 28886995
Breast Cancer Res Treat. 2016 Nov;160(1):51-59
pubmed: 27620882
Cancer Biother Radiopharm. 2016 Sep;31(7):238-45
pubmed: 27563805
Methods Mol Biol. 2022;2364:299-318
pubmed: 34542859
J Control Release. 2018 Apr 10;275:129-141
pubmed: 29408580
Adv Exp Med Biol. 2021;1295:29-48
pubmed: 33543454
Front Endocrinol (Lausanne). 2021 Sep 23;12:760153
pubmed: 34630338
Diabetes Obes Metab. 2022 Feb;24(2):321-326
pubmed: 34622548
Pharmaceuticals (Basel). 2022 Apr 27;15(5):
pubmed: 35631367
J Nucl Med. 2021 Oct;62(10):1406-1414
pubmed: 33579805
Sci Adv. 2016 May 06;2(5):e1600349
pubmed: 27386551
Eur J Pharm Biopharm. 2012 Feb;80(2):368-78
pubmed: 22061263
Commun Biol. 2021 Feb 12;4(1):197
pubmed: 33580154
Theranostics. 2020 Jul 9;10(18):8162-8178
pubmed: 32724464
Bioconjug Chem. 2018 Dec 19;29(12):3967-3981
pubmed: 30485070
Bioconjug Chem. 2009 May 20;20(5):932-6
pubmed: 19413309
Drug Dev Res. 2017 Jun;78(3-4):129-134
pubmed: 28449192
EJNMMI Res. 2021 Apr 12;11(1):37
pubmed: 33846870
Adv Protein Chem Struct Biol. 2015;98:1-55
pubmed: 25819275
Methods Mol Biol. 2022;2371:355-372
pubmed: 34596858
Pharmaceuticals (Basel). 2019 Jul 29;12(3):
pubmed: 31362406
Curr Med Chem. 2022;29(5):881-893
pubmed: 34544332
Chem Commun (Camb). 2011 Aug 28;47(32):9116-8
pubmed: 21735001
Molecules. 2022 Mar 21;27(6):
pubmed: 35335393
Lancet Oncol. 2018 Jun;19(6):799-811
pubmed: 29753703
Eur J Med Chem. 2021 Feb 5;211:113018
pubmed: 33223264
Cancer Discov. 2021 Dec 1;11(12):2951-2952
pubmed: 34666990
Theranostics. 2018 Jan 1;8(4):1121-1130
pubmed: 29464003
Biochim Biophys Acta. 2000 Jun 1;1475(1):90-8
pubmed: 10806343
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Mol Pharm. 2019 Jan 7;16(1):165-172
pubmed: 30521347
Nutr J. 2016 Dec 1;15(1):99
pubmed: 27903278
EJNMMI Res. 2014 Dec;4(1):30
pubmed: 26055935
Anal Chem. 2019 Jul 2;91(13):8383-8389
pubmed: 31140782
Eur J Med Chem. 2021 Oct 5;221:113572
pubmed: 34087497
Genes Dis. 2017 Feb 10;4(1):1-3
pubmed: 30258901
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):395-405
pubmed: 32621132
Mol Pharm. 2019 Jun 3;16(6):2636-2647
pubmed: 31067065
Bioconjug Chem. 2019 Mar 20;30(3):525-530
pubmed: 30735042
Aliment Pharmacol Ther. 1995 Aug;9(4):363-78
pubmed: 8527612
Soft Matter. 2020 Jun 24;16(24):5759-5769
pubmed: 32530018
J Med Chem. 2022 Jan 13;65(1):876-884
pubmed: 34981929
Eur J Med Chem. 2020 Jul 15;198:112389
pubmed: 32388115
Nucleic Acids Res. 2016 Jan 4;44(D1):D1098-103
pubmed: 26586798
Eur J Med Chem. 2021 Mar 5;213:113050
pubmed: 33280896
Adv Drug Deliv Rev. 2017 Feb;110-111:112-126
pubmed: 27370248
Protein Pept Lett. 2018;25(6):514-521
pubmed: 29848260
J Pharm Sci. 2019 Jul;108(7):2465-2475
pubmed: 30790581
Bioconjug Chem. 2019 Jul 17;30(7):2011-2022
pubmed: 31243977
Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):202-8
pubmed: 18991788
Pharmaceutics. 2020 Jun 22;12(6):
pubmed: 32580307
Beilstein J Org Chem. 2018 Apr 26;14:930-954
pubmed: 29765474
J Control Release. 2012 Jun 28;160(3):477-85
pubmed: 22542699
Asian J Pharm Sci. 2020 Jul;15(4):416-448
pubmed: 32952667
Eur J Med Chem. 2015 Apr 13;94:459-70
pubmed: 25591543
Nano Lett. 2020 Jun 10;20(6):4153-4161
pubmed: 32462880
Mol Cancer Ther. 2012 Feb;11(2):308-16
pubmed: 22203732
Cell Signal. 2017 Aug;36:108-116
pubmed: 28473198
Cancer Sci. 2021 Oct;112(10):4317-4334
pubmed: 34314556
ChemMedChem. 2014 Jul;9(7):1403-12
pubmed: 24677792
Chem Biol Drug Des. 2020 Jan;95(1):58-65
pubmed: 31452330
J Nucl Med. 2012 May;53(5):787-95
pubmed: 22499613
J Nucl Med. 2017 Oct;58(10):1706
pubmed: 28280224
Mol Pharm. 2020 Sep 8;17(9):3165-3176
pubmed: 32787278
Future Med Chem. 2018 Sep 1;10(18):2201-2226
pubmed: 30043641
Adv Exp Med Biol. 2017;1030:167-184
pubmed: 29081054
Pharmaceutics. 2020 Feb 03;12(2):
pubmed: 32028608
Drug Metab Pharmacokinet. 2019 Feb;34(1):42-54
pubmed: 30573392
Nat Commun. 2021 Aug 26;12(1):5131
pubmed: 34446736
Nanomedicine (Lond). 2022 Oct;17(24):1855-1869
pubmed: 35311343
Acta Biomater. 2019 Mar 15;87:130-139
pubmed: 30665017
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31212948
Breast Cancer Res Treat. 2020 Apr;180(2):379-384
pubmed: 32034579
Pharm Res. 2009 Nov;26(11):2486-94
pubmed: 19774344
Gut. 1994;35(3 Suppl):S1-4
pubmed: 7911441
J Control Release. 2001 Jul 6;74(1-3):129-34
pubmed: 11489489
EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4
pubmed: 31997090
Macromol Biosci. 2022 Feb;22(2):e2100299
pubmed: 34791790
J Med Chem. 2001 Apr 26;44(9):1341-8
pubmed: 11311056
Chem Soc Rev. 2015 Jan 7;44(1):91-102
pubmed: 25199043
Chem Biol. 2003 Mar;10(3):201-2
pubmed: 12670531
Bioanalysis. 2021 Jan;13(2):101-113
pubmed: 33496610
J Med Chem. 2021 Jan 28;64(2):991-1000
pubmed: 33417771
Hemasphere. 2022 Feb 25;6(3):e687
pubmed: 35243210
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1695
pubmed: 33470550
PLoS One. 2012;7(4):e35187
pubmed: 22523575
Cancer Lett. 2021 Jul 28;511:15-25
pubmed: 33945837
Int J Cancer. 2018 Sep 1;143(5):1188-1201
pubmed: 29582409
Cancer Biother Radiopharm. 2014 May;29(4):179-87
pubmed: 24820805
J Biosci Bioeng. 2020 May;129(5):613-618
pubmed: 31839388
Clin Cancer Res. 2013 Mar 15;19(6):1567-76
pubmed: 23349317
Clin Cancer Res. 2018 Jul 15;24(14):3242-3246
pubmed: 29476018
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1879-88
pubmed: 24973039
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616557
Pharmacol Rev. 2022 Jul;74(3):680-711
pubmed: 35710136
J Pediatr Gastroenterol Nutr. 2022 Jan 1;74(1):1-6
pubmed: 34508049
MAbs. 2022 Jan-Dec;14(1):2044977
pubmed: 35275041
Diagnostics (Basel). 2021 Sep 30;11(10):
pubmed: 34679505
Molecules. 2019 Aug 16;24(16):
pubmed: 31426442
Mol Cancer Ther. 2020 Jul;19(7):1385-1394
pubmed: 32398269
Biomolecules. 2021 Dec 04;11(12):
pubmed: 34944476
J Med Chem. 2021 Jan 14;64(1):216-232
pubmed: 33382619
Integr Biol (Camb). 2010 Aug;2(7-8):326-37
pubmed: 20657951
Drug Deliv. 2016 Jun;23(5):1734-46
pubmed: 25853477
Clin Neurophysiol. 2021 Oct;132(10):2532-2539
pubmed: 34455311
Beilstein J Org Chem. 2014 May 22;10:1197-212
pubmed: 24991269
Nat Rev Drug Discov. 2020 Apr;19(4):277-289
pubmed: 31848464
Hell J Nucl Med. 2015 Sep-Dec;18(3):193-8
pubmed: 26574690
EJNMMI Res. 2022 Apr 11;12(1):20
pubmed: 35403915
Adv Sci (Weinh). 2020 Dec 21;8(3):2001960
pubmed: 33552853
Am J Cancer Res. 2020 Apr 01;10(4):1045-1067
pubmed: 32368385
J Chem Theory Comput. 2022 Apr 12;18(4):2720-2736
pubmed: 35298162
Pharm Res. 2002 May;19(5):609-14
pubmed: 12069162
Amino Acids. 2006 Jun;30(4):351-67
pubmed: 16622600
Beilstein J Org Chem. 2018 Jun 7;14:1378-1388
pubmed: 29977402
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1465-74
pubmed: 11350742
J Med Chem. 2015 Sep 24;58(18):7370-80
pubmed: 26308095
Int J Mol Sci. 2021 Feb 06;22(4):
pubmed: 33562082
J Nanobiotechnology. 2018 Mar 30;16(1):34
pubmed: 29602308
Chem Biol. 2003 Mar;10(3):233-9
pubmed: 12670537
Bioconjug Chem. 2019 Feb 20;30(2):432-442
pubmed: 30615416
J Food Biochem. 2019 Jan;43(1):e12571
pubmed: 31353489
Front Pharmacol. 2021 Oct 06;12:695182
pubmed: 34690750
Cancers (Basel). 2020 Jun 07;12(6):
pubmed: 32517329
Drugs. 2019 Sep;79(13):1467-1475
pubmed: 31352604
Molecules. 2021 Oct 05;26(19):
pubmed: 34641586
Front Pharmacol. 2022 Jan 12;12:816896
pubmed: 35095531
J Med Chem. 2019 Mar 14;62(5):2708-2719
pubmed: 30735385
Angew Chem Int Ed Engl. 1998 Dec 17;37(23):3281-3284
pubmed: 29711420
Food Funct. 2020 May 1;11(5):4146-4159
pubmed: 32347864
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5335-8
pubmed: 26421991
Acta Pharm Sin B. 2020 Jul;10(7):1249-1250
pubmed: 32834951
Molecules. 2021 Jan 12;26(2):
pubmed: 33445797
Clin Nucl Med. 2019 Jun;44(6):452-458
pubmed: 30985413
ChemMedChem. 2010 Apr 6;5(4):567-74
pubmed: 20222099
J Drug Target. 1999;7(1):55-63
pubmed: 10614815
Biomaterials. 2021 Nov;278:121139
pubmed: 34624753
J Labelled Comp Radiopharm. 2017 Jul;60(9):431-438
pubmed: 28545160
Mol Cancer Ther. 2022 Apr 1;21(4):568-581
pubmed: 35149549
Clin Toxicol (Phila). 2017 Feb;55(2):88-96
pubmed: 28084171